Agios Pharmaceuticals reports positive Phase 3 ENERGIZE study results for mitapivat in non-transfusion-dependent thalassemia, increasing hemoglobin response rates vs. placebo.

Agios Pharmaceuticals reports positive Phase 3 ENERGIZE study results for mitapivat in non-transfusion-dependent alpha- or beta-thalassemia. Mitapivat increased hemoglobin response rates vs. placebo, showing potential for treating both transfusion-dependent and non-transfusion-dependent thalassemia subtypes. The company aims to file for US approval by year-end, using data from both ENERGIZE and ENERGIZE-T studies.